FDC (NSE:FDC) Interest Income : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is FDC Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. FDC's interest income for the three months ended in Mar. 2024 was ₹0 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2024 was ₹0 Mil.

FDC Interest Income Historical Data

The historical data trend for FDC's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FDC Interest Income Chart

FDC Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Income

Get a 7-Day Free Trial

76.77

119.88

230.43

238.16

FDC Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Income	Get a 7-Day Free Trial															-	-	-	-	-

FDC Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

FDC (NSE:FDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FDC Ltd (NSE:FDC) » Definitions » Interest Income

Traded in Other Exchanges

531599:India

Address

C-3 Skyvistas, Near Versova Police Station, D.N. Nagar, Andheri (West), Mumbai, MH, IND, 400053

Website

https://www.fdcindia.com

FDC Ltd is an Indian-based pharmaceutical company with USFDA and UK-MHRA-approved API and formulations manufacturing facilities. It has its presence in numerous therapeutic segments: Anti-infectives, Gastro-Intestinal, Vitamins/Minerals/Nutrients, Ophthalmology/Otologicals, Cardiac, Dermatology, Respiratory, Gynaecology, and Others. The company's brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm. The majority of the revenue is generated domestically.